1. Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer
   Yuki Katayama et al, 2023, npj Precision Oncology CrossRef
2. Structure-Based Design of a Potent and Selective Covalent Inhibitor for SRC Kinase That Targets a P-Loop Cysteine
   Guangyan Du et al, 2020, Journal of Medicinal Chemistry CrossRef
3. Polyclonal on- and off-target resistance mutations in an EML4-ALK positive non-small cell lung cancer patient under ALK inhibition
   Marcel Kemper et al, 2021, Oncotarget CrossRef
4. ALK-Positive Non-Small Cell Lung Cancer; Potential Combination Drug Treatments
   Shrestha Nensi et al, 2021, Current Cancer Drug Targets CrossRef
5. Experimental Determination of Cancer Drug Targets with Independent Mechanisms of Resistance
   John C. Ashton et al, 2022, Current Cancer Drug Targets CrossRef
6. Concurrent inhibition of ALK and SRC kinases disrupts the ALK lung tumor cell proteome
   Alberto Diaz-Jimenez et al, 2024, Drug Resistance Updates CrossRef
7. Establishment of an acquired lorlatinib-resistant cell line of non-small cell lung cancer and its mediated resistance mechanism
   Bo Xie et al, 2022, Clinical and Translational Oncology CrossRef
8. EML4‐ALK biology and drug resistance in non‐small cell lung cancer: a new phase of discoveries
   Mariam Elshatlawy et al, 2023, Molecular Oncology CrossRef
9. Safety and Activity of the Combination of Ceritinib and Dasatinib in Osteosarcoma
   Olaf Beck et al, 2020, Cancers CrossRef
10. EML4-ALK induces cellular senescence in mortal normal human cells and promotes anchorage-independent growth in hTERT-transduced normal human cells
    Akihiko Miyanaga et al, 2021, BMC Cancer CrossRef
11. Lorlatinib as a treatment for ALK-positive lung cancer
    Keisuke Baba et al, 2022, Future Oncology CrossRef
12. Anti-diabetic drug metformin inhibits cell proliferation and tumor growth in gallbladder cancer via G0/G1 cell cycle arrest
    Takuma Yamashita et al, 2020, Anti-Cancer Drugs CrossRef
13. Prospective observational study to explore genes and proteins predicting efficacy and safety of brigatinib for ALK-gene rearranged non-small-cell lung cancer: study protocol for ABRAID study (WJOG11919L)
    Yuichi Ozawa et al, 2024, Therapeutic Advances in Medical Oncology CrossRef
14. ALK Inhibitors-Induced M Phase Delay Contributes to the Suppression of Cell Proliferation
    Sirajam Munira et al, 2020, Cancers CrossRef
15. Good clinical response to alectinib, a second generation ALK inhibitor, in refractory neuroblastoma
    John A. Heath et al, 2018, Pediatric Blood & Cancer CrossRef
16. The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer
    Shirish M Gadgeel, 2018, Future Oncology CrossRef
17. Unraveling the Potential of ALK-Targeted Therapies in Non-Small Cell Lung Cancer: Comprehensive Insights and Future Directions
    Hannaneh Parvaresh et al, 2024, Biomedicines CrossRef
18. GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancer
    Yuki Shimizu et al, 2022, npj Precision Oncology CrossRef
19. Current Knowledge about Mechanisms of Drug Resistance against ALK Inhibitors in Non-Small Cell Lung Cancer
    Elisabeth Smolle et al, 2021, Cancers CrossRef
20. Rack1 mediates Src binding to drug transporter P-glycoprotein and modulates its activity through regulating Caveolin-1 phosphorylation in breast cancer cells
    Yanling Fan et al, 2019, Cell Death & Disease CrossRef
21. Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective
    Yang Yang et al, 2022, Signal Transduction and Targeted Therapy CrossRef